Association of cholesteryl ester transfer protein genotypes with paraoxonase-1 activity, lipid profile and oxidative stress in type 2 diabetes mellitus: A study in San Luis, Argentina

Journal of Diabetes Investigation

Volumn 6, Issue 1, 2015, Pages 67-77

  Siewert, Susana ^a   Gonzalez, Irma Ines ^a   Lucero, Roberto Osvaldo ^b   Ojeda, Marta Susana ^a  

^a UNIVERSIDAD NACIONAL DE SAN LUIS   (Argentina)

^b Juana Koslay Health Center   (Argentina)

Author keywords

Oxidative stress; Polymorphism; Type 2 diabetes mellitus

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CATALASE; CHOLESTEROL ESTER TRANSFER PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

ADULT; ARGENTINA; ARTICLE; ATHEROGENESIS; CATALYSIS; CETP GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA FRAGMENTATION; DNA POLYMORPHISM; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC TRAIT; GENETIC VARIABILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYDROLYSIS; INSULIN RESISTANCE; LIPID ANALYSIS; LIPOPROTEIN METABOLISM; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PON 1 GENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84920273780     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12256     Document Type: Article

References (63)

1. Juutilainen A, Lehto S, Rönnemaa T, et al. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005; 28: 2901-2907.
2. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-458.
3. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2000; 23(Suppl 1): S57-S60.
4. Van J, Pan J, Charles MA, et al. Atherogenic lipid phenotype in a general group of subjects. Arch Pathol Lab Med 2007; 131: 1679-1685.
5. Syvänne M, Ahola M, Lahdenperä S, et al. High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease. J Lipid Res 1995; 36: 573-582.
6. Soran H, Hama S, Yadav R, et al. HDL functionality. Curr Opin Lipidol 2012; 23: 353-366.
7. Kronenberg F, Coon H, Ellison RC, et al. Segregation analysis of HDL cholesterol in the NHLBI Family Heart Study and in Utah pedigrees. Eur J Hum Genet 2002; 10: 367-374.
8. Pérusse L, Rice T, Després JP, et al. Familial resemblance of plasma lipids, lipoproteins and postheparin lipoprotein and hepatic lipases in the HERITAGE Family Study. Arteriocler Thromb Vasc Biol 1997; 17: 3263-3269.
9. Pietiläinen KH, Söderlund S, Rissanen A, et al. HDL subspecies in young adult twins: heritability and impact of overweight. Obesity (Silver Spring) 2009; 17: 1208-1214.
10. Weissglas-Volkov D, Pajukanta P. Genetic causes of high and low serum HDL-cholesterol. J Lipid Res 2010; 51: 2032-2057.
11. Groener JE, Van Rozen AJ, Erkelens DW. Cholesteryl ester transfer activity. Localization and role in distribution of cholesteryl ester among lipoproteins in man. Atherosclerosis 1984; 50: 261-271.
12. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008; 299: 2777-2788.
13. Thompson JF, Durham LK, Lira ME, et al. CETP polymorphisms associated with HDL cholesterol may differ from those associated with cardiovascular disease. Atherosclerosis 2005; 181: 45-53.
14. Oliveira HC, Ma L, Milne R, et al. Cholesteryl ester transfer protein activity enhances plasma cholesteryl ester formation. Studies in CETP transgenic mice and human genetic CETP deficiency. Arterioscler Thromb Vasc Biol 1997; 17: 1045-1052.
15. Groener JR, Van Rozen AJ, Erkelens DW. Cholesteryl ester transfer activity. Localization and role in distribution of cholesteryl ester among lipoproteins in man. Atherosclerosis 1984; 50: 261-271.
16. Stein O, Stein Y. Atheroprotective mechanisms of HDL. Atherosclerosis 1999; 144: 285-301.
17. Bruce C, Tall AR. Cholesteryl ester transfer proteins, reverse cholesterol transport, and atherosclerosis. Curr Opin Lipidol 1995; 6: 306-311.
18. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987; 3: 463-524.
19. Zheng KQ, Zhang SZ, He Y, et al. Association between cholesteryl ester transfer protein gene polymorphisms and variations in lipid levels in patients with coronary heart disease. Chin Med J (Engl) 2004; 117: 1288-1292.
20. Fielding CJ, Havel RJ. Cholesteryl ester transfer protein: friend or foe? J Clin Invest 1996; 97: 2687-2688.
21. Ridker PM, Paré G, Parker AN, et al. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet 2009; 2: 26-33.
22. Heidema AG, Feskens EJ, Doevendans PA, et al. Analysis of multiple SNPs in genetic association studies: comparison of three multilocus methods to prioritize and select SNPs. Genet Epidemiol 2007; 31: 910-921.
23. Brousseau ME, O'Connor JJ Jr, Ordovas JM, et al. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler Thromb Vasc Biol 2002; 22: 1148-1154.
24. Riemens S, van Tol A, Sluiter W, et al. Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 1998; 140: 71-79.
25. Heller DA, de Faire U, Pedersen NL, et al. Genetic and environmental influences on serum lipid levels in twins. N Engl J Med 1993; 328: 1150-1156.
26. Corsetti JP, Ryan D, Rainwater DL, et al. Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels. Arterioscler Thromb Vasc Biol 2010; 30: 1657-1664.
27. Gur M, Yildiz A, Demirbag R, et al. Paraoxonase and arylesterase activities in patients with cardiac syndrome X, and their relationship with oxidative stress markers. Coron Artery Dis 2007; 18: 89-95.
28. Abbott CA, Mackness MI, Kumar S, et al. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15: 1812-1818.
29. Mackness MI, Harty D, Bhatnagar D, et al. Serum paraoxonase activity in familial hypercholesterolemia and insulin dependent diabetes mellitus. Atherosclerosis 1991; 86: 193-199.
30. Odawara M, Tachi Y, Yamashita K. Paraoxonase polymorphism (Gln 191-Arg) is associated with coronary heart disease in Japanese noninsulin- dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 2257-2260.
31. Mackness MI, Mackness B, Durrington PN, et al. Paraoxonases biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7: 69-76.
32. Navab M, Berliner JA, Watson AD, et al. The Ying and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996; 16: 831-842.
33. Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-1590.
34. Octaviano FG, Handy DE, Loscalzo J. Redox regulation in the extracellular environment. Circ J 2008; 72: 1-16.
35. Seino Y, Nanjo K, Tajima N, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212-228.
36. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
37. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
38. Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian tissue. Physiol Rev 1979; 59: 527-605.
39. Beltowski J, Wójcicka G, Mydlarczyk M, et al. Cerivastatin modulates plasma paraoxonase/arylesterase activity and oxidant-antioxidant balance in the rat. Pol J Pharmacol 2002; 54: 143-150.
40. Jentzsch AM, Bachmann H, Fürst P, et al. Improved analysis of malondialdehyde in human body fluids. Free Radic Biol Med 1996; 20: 251-256.
41. 2 in aqueous and protein containing samples. Nitric Oxide 1999; 3: 225-234.
42. Fumeron F, Betoulle D, Luc G, et al. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J Clin Invest 1995; 96: 1664-1671.
43. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest 2012; 3: 39-40.
44. Rye KA, Barter PJ. Formation and metabolism of prebeta-migrating, lipid poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2004; 24: 421-428.
45. McLaughlin T, Reaven G, Abbasi F, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol 2005; 96: 399-404.
46. Tabak O, Gelisgen R, Erman H, et al. Oxidative lipid, protein, and DNA damage as oxidative stress markers in vascular complications of diabetes mellitus. Clin Invest Med 2011; 34: E163-E171.
47. Gaidukov L, Tawfik DS. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 2005; 44: 11843-11854.
48. Flekac M, Skrha J, Zídková K, et al. Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol Res 2008; 57: 717-726.
49. Ikeda Y, Suehiro T, Inoue M, et al. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulindependent diabetes mellitus. Metabolism 1998; 47: 598-602.
50. Hedrick CC, Thorpe SR, Fu MX, et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000; 43: 312-320.
51. Selvam R, Anuradha CV. Lipid peroxidation and antiperoxidative enzyme changes in erythrocytes in diabetes mellitus. Indian J Biochem Biophys 1988; 25: 268-272.
52. Tilton WM, Seaman C, Carriero D, et al. Regulation of glycolysis in the erythrocyte: role of the lactate/pyruvate and NAD/NADH ratios. J Lab Clin Med 1991; 118: 146-152.
53. Rye KA, Clay MA, Barter PJ. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 1999; 145: 227-238.
54. Kondo I, Berg K, Drayna D, et al. DNA polymorphism at the locus for human cholesteryl ester transfer protein (CETP) is associated with high density lipoprotein cholesterol and apolipoprotein levels. Clin Genet 1989; 35: 49-56.
55. Noone E, Roche HM, Black I, et al. Effect of postprandial lipaemia and Taq 1B polymorphism of the cholesteryl ester transfer protein (CETP) gene on CETP mass, activity, associated lipoproteins and plasma lipids. Br J Nutr 2000; 84: 203-209.
56. Boekholdt SM, Kuivenhoven JA, Hovingh GK, et al. CETP gene variation: relation to lipid parameters and cardiovascular risk. Curr Opin Lipidol 2004; 15: 393-398.
57. Corella D, Sáiz C, Guillén M, et al. Association of TaqIB polymorphism in the cholesteryl ester transfer protein gene with plasma lipid levels in a healthy Spanish population. Atherosclerosis 2000; 152: 367-376.
58. Dullaart RP, Sluiter WJ, Dikkeschei LD, et al. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 1994; 24: 188-194.
59. Smaoui M, Hammami S, Attia N, et al. Modulation of plasma cholesteryl ester transfer protein activity by unsaturated fatty acids in Tunisian type 2 diabetic women. Nutr Metab Cardiovasc Dis 2006; 16: 44-53.
60. Raynaud E, Perez-Martin A, Brun JF, et al. Revised concept for the estimation of insulin sensitivity from a single sample. Diabetes Care 1999; 22: 1003-1004.
61. Haffner SM, Gonzalez C, Mykkänen L, et al. Total immunoreactive proinsulin, immunoreactive insulin and specific insulin in relation to conversion to NIDDM: the Mexico City Diabetes Study. Diabetologia 1997; 40: 830-837.
62. Castle CK, Kuiper SL, Blake WL, et al. Remodeling of the HDL in NIDDM: a fundamental role for cholesteryl ester transfer protein. Am J Physiol 1998; 274(6 Pt 1): E1091-E1098.
63. Kontush A, Chapman MJ. Functionally defective HDL: a new therapeutic target at the crossroads of dyslipidemia, inflammation and atherosclerosis. Pharmacol Rev 2006; 58: 342-374.